Glucotrack executes 1-for-15 reverse stock split, shares begin adjusted trading August 31
RUTHERFORD, N.J., August 28. A one-for-fifteen reverse stock split cut Glucotrack, Inc.'s shares outstanding from 11,972,157 to approximately 798,144, the company disclosed in an 8-K filed with the SEC. The split became effective at 4:30 p.m. Eastern Time on that date. Common stock on the Nasdaq, ticker GCTK, will begin trading on a split-adjusted basis at market open on August 31.
Key takeaways
- Glucotrack, Inc. completed a one-for-fifteen reverse stock split that reduced shares outstanding from 11,972,157 to approximately 798,144.
- The split became effective at 4:30 p.m. Eastern Time on August 28, and split-adjusted trading on the Nasdaq under ticker GCTK began at market open on August 31.
- Stockholders approved the split at Glucotrack's 2026 annual meeting on August 18, combining every 15 shares into one while par value stayed at $0.001.
- No fractional shares were issued, as holders entitled to fractions were rounded up to the next whole share, and the new CUSIP number is 45824Q887.
- On a post-split basis, Glucotrack reported a net loss per common share of $468.30 for the year ended December 31, 2025, and $36.60 per share for the six months ended June 30, 2026.
RUTHERFORD, N.J., August 28. A one-for-fifteen reverse stock split cut Glucotrack, Inc.'s shares outstanding from 11,972,157 to approximately 798,144, the company disclosed in an 8-K filed with the SEC. The split became effective at 4:30 p.m. Eastern Time on that date. Common stock on the Nasdaq, ticker GCTK, will begin trading on a split-adjusted basis at market open on August 31.
Stockholders approved the split at Glucotrack's 2026 annual meeting on August 18, the filing shows. Under the terms, every 15 issued and outstanding shares of common stock were automatically combined into one. Par value per share remained at $0.001. No fractional shares were issued; holders entitled to fractions received an additional fraction to round up to the next whole share, according to the 8-K.
The total number of authorized shares remains 250,000,000. Outstanding stock options and warrants were adjusted under the same ratio, with corresponding changes to exercise prices, the company said. VStock Transfer, LLC, acting as exchange agent, will send each stockholder of record a transaction statement showing the updated share count. Shareholders holding through a broker or other nominee will see their positions adjusted automatically.
Restated per-share figures
The 8-K restated historical per-share data to reflect the split. On a post-split basis, Glucotrack's net loss per common share was $468.30 for the year ended December 31, 2025, and $61,590 for the year ended December 31, 2024, the filing shows. Comprehensive net losses for those periods were $19,339 thousand and $22,573 thousand, respectively.
For the six months ended June 30, 2026, the company reported a comprehensive net loss of $8,137 thousand, or $36.60 per share post-split, the release shows. That figure breaks down as a $4,331 thousand loss in the first quarter and a $3,806 thousand loss in the second quarter, at $39.75 and $11.40 per share post-split, respectively. Post-split shares outstanding stood at 417,285 as of June 30, 2026.
The ticker symbol remains GCTK on the Nasdaq Stock Market. The new CUSIP number is 45824Q887. Glucotrack is a Delaware corporation headquartered at 301 Route 17 North, Suite 800, Rutherford, New Jersey 07070.